Poster Session Info - October 8th
Poster board dimensions:
4 feet high by 6 feet wide
The boards are equipped with Velcro and pushpins.
| Poster # | Submitter | Title |
| 3 | Matthew Mitcheltree | A New Cryptic Back Pocket Expands KRAS Druggability Beyond Switch-Region Targeting |
| 5 | Shou-Jiang Gao | CASTOR1 Functional Inactivation Drives KRAS-Mutant Lung Cancer and Therapy Resistance by a Noncanonical Mechanism of Tumor Suppression |
| 7 | Anastasiia Gerasimova | Use of a p120RasGAP Glue to Inhibit KRAS in NF1-Null Cells |
| 11 | Liang Xu | Human RanGAP1 and NF1 Share a Conserved Arginine-Finger Mechanism for GTP Hydrolysis |
| 15 | Daniel Bonsor | Molecular mechanism of KRAS binding to BRAF and its regulation by the BRAF-specific region |
| 17 | Atanasio Gomez Mulas | Development of a Potent and Genetically Encoded PDE6D Inhibitor for Definite Target Validation |
| 19 | Goksu Oral Tuzun | Investigation of the Spred/ RAF Interaction and its Impact On RAS Inactivation |
| 21 | Bengi Ruken Yavuz | Single-Cell Mapping of Malignant Signaling Networks Guides Drug Combinations |
| 27 | Geoff Clark | Pan-RAS inhibition suppresses Luminal B breast cancer |
| 29 | Vidushi Trivedi | Wild-type HRAS may contribute to reduced sensitivity to RAS inhibition in KRASQ61H-mutant PDAC |
| 31 | Grace Goodhart | Evaluating Kinase suppressor of RAS 1 (KSR1) as a potential resistance mechanism to KRAS inhibition in pancreatic cancer |
| 33 | Romain Baer | From Design to Discovery: A DCK*-assay development platform for KRAS degraders |
| 35 | Sarah Ackermann | Dynamic regulation of nutrient scavenging pathways in response to RAS inhibition and RAS inhibitor resistance in PDAC |
| 37 | Nancy Jaiswal | Allosteric Coupling of Zn(II) Binding and GTP Hydrolysis in Bacterial ZigA: Role of the RxKG Motif, Linker Dynamics, and CTD-Mediated Self-Gapping |
| 39 | Ji Luo | Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma |
| 41 | Nancy Chen | Characterization of RAS mutations in Glioblastomas |
| 43 | Shohei Koide | RAS lollipop: Protein engineering-enabled cryo-EM Investigation of small GTPases |
| 47 | Fiona Hood | Establishing a Quantitative Proteomics Pipeline for Systematic Quantitation of RAS Network Proteins |
| 49 | Daniel Ritt | An in vitro BRAF Activation Assay Elucidates the Molecular Mechanisms that Drive Disassembly of the Autoinhibited State |
| 51 | Khalilah Taylor | Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma |
| 53 | Seamus Degan | Dordaviprone/ONC201 Mitochondrial ClpP agonist in Combination with RAS Inhibitors Reduces KRAS-mutant Pancreatic Cancer Growth and Bypasses RAS Inhibitor Resistance |
| 55 | Amber Shunshion | RAF conformation biosensors: Dissecting the initiating mechanism of RAS-driven RAF-activation in cells |
| 57 | Wen-Hsuan Chang | KEAP1-NRF2 mediated resistance to KRAS inhibition is overcome by targeting glutamine dependency in pancreatic and lung cancer |
| 59 | Felice Lightstone | Mummi: A Machine Learning-Driven Modeling Infrastructure For Coupling Different Scales, Showcased For Ras-Raf Activation |
| 61 | Sarah Sheppard | From Genotype to Therapy: Preclinical Evaluation of Targeted Treatments for KRAS-Related Complex Lymphatic Anomalies |
| 63 | Peter Jackson | Secretomics of KRAS-G12C Inhibition Reveals TGF-α/EGFR and TGF-β/CK2 Autocrine Effectors of Tumor Growth and Migration |
| 65 | Dylan Aguinaldo | Defining the Role of SHP2 Phosphatase Activity in RAS Signaling |
| 67 | Ireneusz Gorniak | Towards generating fully processed KRAS, HRAS, NRAS for membrane association studies |
| 69 | Jun Zou | A monovalent KRAS degrader (monoCIDE) degrades KRAS through NEDD4 family E3s mediated K88-dependent ubiquitylation |
| 71 | Arun Unni | Understanding the consequences of excess RAS pathway activity in cancer cells |
| 73 | Elizabeth Stover | Efficacy of targeting RAS/RAF/MEK and anti-apoptotic BCL-XL in RAS pathway altered gynecologic cancer models |
| 75 | Gunnar Boysen | Differentiating Epigenetic Marks and DNA Adducts at the KRAS Codon 12 Mutation Hotspot |
| 77 | Venkata Reddy Chirasani | Exploring Biomolecular Complexity: Computational Insights into Human Diseases and and Molecular Mechanisms |
| 79 | Marta Manik | Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis |
| 81 | Clil Regev | Mechanistic Study of ERK Autoinhibition to Guide Drug Combination Therapy |
| 83 | Surbhi Mundra | Getting a handle on redox regulation of KRASG12C and targeted therapies. |
| 87 | Simon Messing | Improvements in purification of RAF1 RAS binding and cysteine-rich domain |
| 89 | Yang Zhang | Daraxonrasib resistance mechanisms in NRAS-mutant melanoma cell lines and potential treatment with direct NRAS(ON) inhibitors |
| 93 | John Witherspoon | Mutant Nrf2E79Q Enhances the Promotion and Progression of a Subset of Oncogenic Ras Keratinocytes and Skin Tumors |
| 95 | Hebei Lin | EphA2 Signaling Restrains RAS–ERK Pathway Activation but Promotes Immune Evasion During Hepatocellular Carcinogenesis |
| 97 | Rodrigo Enrique Cáceres Gutiérrez | Spatiotemporal control of RAS-RAF signaling at the single-molecule level |
| 99 | Jessica Das | Uncovering the role of IMP2 in RAS signaling and colorectal cancer progression |
| 101 | Victoria Gonzalez | Pulse-SILAC proteomics identifies selective translation as a control point for a KRAS-regulated secretory program in lung cancer |
| 103 | Oluwadara Coker | The TEAD-dependent transcriptome integrates with RHO GTPase activation to drive resistance to RAS inhibition in PDAC |
| 105 | Nadege Gitego | BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS (ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models |
| 107 | Adrij Mohan | Characterization Of Cw-11055, A Novel Potent KRAS Degrader In Pancreatic Cancer |
| 109 | Tamar Green | SHP2 activation level scales with autism-related behavior and subcortical brain structure in Noonan syndrome |
| 111 | Saman Setoodeh | BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, demonstrates antitumor activity alone and in combination with KRAS inhibitors in KRAS-mutant models without inducing hyperglycemia |
| 113 | Kuo-Hui Su | HSF1 Sustains Mitochondrial Lipoylation Under Copper Toxicity in KRAS-Driven Pancreatic Ductal Adenocarcinoma |
| 115 | Jacob Potter | Structure of SHOC2-KRAS-PP1C Complex Reveals RAS Isoform-Specific Determinants and Insights into Targeting Complex Assembly by RAS inhibitors |
| 117 | Neeraj Tirunagari | SRC-mediated YAP/TAZ/TEAD activation drives acquired resistance to the dual ON/OFF KRASG12C inhibitor BBO-8520 in non-small cell lung cancer |
| 119 | Natalie Thielen | High-Throughput Screening Identifies NT-1 as a Dual JAK3/EGFR Inhibitor that Overcomes KRAS Inhibitor Resistance in Colorectal Cancer |